FDA gets expanded Power to prevent Medical Device Supply Disruptions
Due to the Corona pandemic, there were supply shortages of medical device products in the USA. To get these shortages under control in the future, the FDA gets expanded power. What is planned?
First of all, financial resources are being allocated for a supply shortage prevention program. That's as much as $21.6 million the U.S. has budgeted for the Resilient Supply Chain and Shortages Prevention Program (RSCSPP) in fiscal year 2022. The program runs in conjunction with the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The focus is on strengthening the nation's supply chains, including becoming less dependent on medical devices manufactured outside the United States. For that purpose, preventive measures need to be taken. For example, potential supply chain disruptions of medical devices need to be identified and the continuous monitoring of supply chains needs to be established to be able to intervene quickly. To this end, FDA capabilities are to be further strengthened.
Please see the FDA Website to find further information.
Related GMP News
27.05.2026Survey Results from Team Notified Body on the MDR and IVDR
27.05.2026FDA Q&A Document on the new GMP Regulations for Medical Devices
27.05.2026CDRH Annual Report 2025
13.01.2026MDCG publishes Guidance on the Surveillance of Medical Devices and IVDs
13.01.2026Real-world Evidence Data now also expanded in the Field of Medical Devices
06.11.2025FDA Warning Letter Statistics on Medical Devices in the Past Fiscal Year 2025